Free tool
Oncology stocks
We cover 31 companies grouped under the Oncology theme. The median market value in the group is $6.39B. Across the group, the median move over the past trading day is +1.97%. 87% of the 31 with a 200-day average trade above it. Price change over the past year runs from −14.4% to +486.0% across the middle 80 percent of the group, with a median of +79.6%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
31 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% | Oct 29, 2026 |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $73.00B | Large cap | +12.47% | Oct 27, 2026 |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% | Nov 4, 2026 |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +21.95% | Nov 5, 2026 |
| 4568.T | Daiichi Sankyo Company, Limited | $33.36B | Large cap | −15.95% | Oct 30, 2026 |
| BNTX | BioNTech SE | $28.65B | Large cap | +8.55% | Nov 3, 2026 |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% | Oct 27, 2026 |
| GMAB | Genmab A/S | $21.42B | Large cap | +41.34% | Nov 5, 2026 |
| GE9.DE | GENMAB AS N | $21.11B | Large cap | −14.41% | Nov 5, 2026 |
| 0J9P.L | Incyte Corporation | $21.10B | Large cap | +53.55% | Oct 27, 2026 |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% | Oct 27, 2026 |
| 0IJO.L | Exelixis, Inc. | $14.05B | Large cap | +44.33% | Oct 27, 2026 |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% | Oct 19, 2026 |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +62.22% | Oct 29, 2026 |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% | Nov 3, 2026 |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% | Nov 11, 2026 |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% | Nov 5, 2026 |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% | Nov 4, 2026 |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% | Nov 2, 2026 |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% | Nov 4, 2026 |
| NANO.PA | Nanobiotix S.A. | $2.12B | Mid cap | +341.09% | Sep 29, 2026 |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% | Sep 29, 2026 |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% | Oct 29, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.